Announcements Trials

Browse Landscape

Phase

Status

Terminated 2 Completed 2 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 9 Recurrence 1 Oligodendroglioma 1 Neoplasms 1 Neoplasm Recurrence, Local 1 Medulloblastoma 1 Lymphoma, Large B-Cell, Diffuse 1 Glioma 1 Central Nervous System Neoplasms 1 Burkitt Lymphoma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Cyclophosphamide 21 venetoclax 18 pembrolizumab 16 Dexamethasone 16 fludarabine 14 Cytarabine 13 Gemcitabine 9 pomalidomide 8 Rituximab 8 Carboplatin 8 Azacitidine 8 glofitamab 7 fludarabine phosphate 7 Lenalidomide 7 Immunotherapy, Adoptive 7 selinexor 6 Paclitaxel 6 Injections 6 Granulocyte Colony-Stimulating Factor 6 Cisplatin 6 daratumumab 5 Temozolomide 5 Oxaliplatin 5 Bevacizumab 5 zanubrutinib 4 ruxolitinib 4 Surgical Procedures, Operative 4 Nivolumab 4 Drug Therapy 4 Decitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × Lomustine × Clear all

NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡